Abstract
Objective
The aim of this study was to determine the absolute oral bioavailability of fluticasone propionate (FP) in healthy volunteers.
Methods
A 3-period incomplete block crossover design was used. On separate occasions, 21 male volunteers received a single 250μg intravenous dose of FP (n = 21) and twice daily oral doses of either micronised FP 0.1mg (n = 9), 1mg (n = 12), 10mg (n = 11) or placebo (n = 9) for 4 days.
Results
FP was not measurable in the plasma after twice daily oral administration of a 0. 1mg dose. FP concentrations just above the limit of quantification could be measured in only 5 volunteers, and only at some time points, after administration of FP 1mg twice daily. At a dose of 10mg twice daily the absolute oral bioavailability of the drug was <1% when a liquid chromatography-mass spectrometry assay was used to assess plasma concentrations. Only oral doses of FP 10mg twice daily, 10 times greater than the recommended maximum inhaled dose, produced any detectable change in urinary cortisol excretion.
Conclusion
The results of this study confirm that oral absorption of FP into the systemic circulation is negligible. The swallowed portion of an inhaled dose of FP is unlikely to increase the systemic exposure to the drug, thus decreasing the likelihood of adverse systemic effects.
Similar content being viewed by others
References
Ventresca GP, Mackie AE, Moss JA, et al. Absorption of oral fluticasone propionate in healthy subjects. Am J Respir Crit Care Med 1994; 149: A214.
Mackie AE, Falcoz C, McDowall JE, et al. Phannacokinetics of fluticasone propionate inhaled from the Diskhaler® and the Diskus® powder devices in healthy subjects. Br J Clin Pharmacol 1997; 43: 540P–1P.
Bain BM, Harrison G, Jenkins KD, et al. A sensitive radioim-munoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma. J Pharm Biomed Anal 1993; 11: 557–61.
Jones AE, Callejas S, Sadra P, et al. The determination of drugs for the treatment of asthma in plasma by automated solid phase extraction and LC-MS. Proceedings of the 45th ASMS Conference on Mass Spectrometry and Allied Topics; 1997 Jun 1–5; Palm Springs, CA: 560.
Rowland M, Tozer TN, editors. Clinical phannacokinetics: concepts and applications. 3rd ed. Philadelphia: Williams & Wilkins, 1995.
Barnes NC, Hallett C, Harris TA. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998; 92(1): 95–104.
Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332(13): 868–75.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Falcoz, C., Oliver, R., McDowall, J.E. et al. Bioavailability of Orally Administered Micronised Fluticasone Propionate. Clin Pharmacokinet 39 (Suppl 1), 9–15 (2000). https://doi.org/10.2165/00003088-200039001-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200039001-00002